



A PHASE 4 STUDY OF HYPERCORTISOLISM IN PATIENTS WITH DIFFICULT-TO-CONTROL TYPE 2 DIABETES DESPITE RECEIVING STANDARD-OF-CARE THERAPIES, ASSESSING PREVALENCE AND TREATMENT WITH MIFEPRISTONE

PRESENTERS:

Richard J. Auchus, MD, PhD, & Daniel Einhorn, MD, FACP, MACE, FRSM

Contact: deinhorn@corcept.com

Juan P. Frias¹, Richard J. Auchus², Irina Bancos³, Lawrence Blonde⁴, Robert S. Busch⁵, John B. Buse⁶, Ralph A. DeFronzo⁷, James W. Findling⁸, Vivian Fonseca⁹, Oksana Hamidi¹⁰, Yehuda Handelsman¹¹, Richard E. Pratley¹², Julio Rosenstock¹³, Iulia Cristina Tudor¹⁴, Andreas G. Moraitis¹⁴, Daniel Einhorn¹⁴

¹Velocity Clinical Research, Los Angeles, CA; ²University of Michigan, Ann Arbor, MI; ³Mayo Clinic, Rochester, MN; ⁴Ochsner Diabetes Clinical Research Unit, Frank Riddick Diabetes Institute, Ochsner Health, New Orleans, LA; ⁵Albany Medical College: Community Endocrine Group, Albany, NY; ⁶University of North Carolina School of Medicine, Chapel Hill, NC; ⁷UT Health Science Center, San Antonio, TX; ⁸Medical College of Wisconsin, Milwaukee, WI; ⁹Tulane University, New Orleans, LA; ¹⁰UT Southwestern Medical Center, Dallas, TX; ¹¹Metabolic Institute of America, Tarzana, CA; ¹²AdventHealth Translational Research Institute, Orlando, FL; ¹³Velocity Clinical Research at Medical City Dallas, Dallas, TX; ¹⁴Corcept Therapeutics Incorporated, Menlo Park, CA.

Please refer to meeting app for conflict of interest disclosures.

Summary & Conclusions

- Primary hypercortisolism is under-recognized.
- Even in the absence of classic Cushingoid features, all degrees of hypercortisolism are associated with significant morbidity and mortality.
- Primary hypercortisolism has been shown to be particularly common in persons with difficult-to-control T2D, but reliable prevalence estimates are currently lacking.
- CATALYST is the first prospective study to assess the prevalence of primary hypercortisolism and the benefit of cortisol-directed medical treatment of primary hypercortisolism in persons with difficult-to-control T2D.
 - Hypercortisolism prevalence is being assessed based on risk factors and screening with DST; ACTH, DHEAS, and adrenal CT scan are being used for further evaluation.
 - Medical therapy with the glucocorticoid receptor antagonist Korlym® (mifepristone) is being evaluated in this population in a prospective, placebo-controlled, randomized design.
- CATALYST is currently enrolling.

ACTH, adrenocorticotropic hormone; CT, computed tomography; DST, dexamethasone suppression test; DHEAS, dehydroepiandrosterone sulfate; T2D, type 2 diabetes.


The authors want to thank all those who are participating in this study: The study participants and their families, the investigators, and the sponsor team.



Background


Primary Hypercortisolism: An Under-recognized, Serious Disease

- Primary hypercortisolism is caused by ACTH-independent, autonomous cortisol secretion by the adrenal glands.
- The understanding of primary hypercortisolism and its clinical significance have evolved significantly in recent years.
 - Primary hypercortisolism may be more common than generally appreciated.¹
 - Even in the absence of the classical physical features of Cushing syndrome², persons with all degrees of primary hypercortisolism have an increased risk of cardiovascular (CV) events, comorbidities, and mortality, even if comorbidities are managed.³⁻⁵
 - Difficult-to-control T2D, treatment-resistant hypertension, and/or osteoporosis may be clinical manifestations of primary hypercortisolism.⁶



Prevalence of Primary Hypercortisolism in Persons with T2D

- Prevalence estimates vary widely.
- Prevalence may be especially high in those with difficult-to-control and/or advanced (multiple therapies and comorbidities) T2D.⁶⁻¹²
- Current prevalence estimates are limited by small sample sizes, different definitions of hypercortisolism, varying degrees of severity of T2D and comorbidities, retrospective designs, ascertainment bias, and incomplete data.



Screening for Primary Hypercortisolism

- **Recommended screening test:** 1-mg overnight DST
 - Post-DST serum cortisol >1.8 µg/dL indicates autonomous cortisol secretion¹⁴, along with adequate dexamethasone level and suppressed early-morning ACTH.
 - Adrenal CT can determine the presence or absence of adrenal adenoma(s) in persons with abnormal DST and ACTH.
- 24-hour urinary free cortisol is frequently normal in persons with adrenal autonomous cortisol secretion.¹
- Late-night salivary cortisol may have low sensitivity for predicting adrenal autonomous cortisol secretion.¹⁵

Premise

- There is a significant need to better understand the prevalence of primary hypercortisolism in persons with difficult-to-control T2D and whether medical treatment of hypercortisolism may result in better control of hyperglycemia and other hypercortisolism-associated comorbidities.
- CATALYST is the first prospective study designed to answer these questions.
- Korlym® (mifepristone), a competitive glucocorticoid receptor antagonist indicated to control hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing syndrome who have T2D or glucose intolerance and have failed surgery or are not candidates for surgery, is used in the treatment phase of the study.

References


- Chiodini I. *J Clin Endocrinol Metab.* 2011;96(5):1223–36.
- Vaidya A et al. *Endocr Pract.* 2019;25(2):178–92.
- Di Dalmazi G et al. *Lancet Diabetes Endocrinol.* 2014;2(5):396–405.
- Petramala L et al. *Endocrine.* 2020;70(1):150–63.
- Elhassan YS, et al. *Ann Intern Med.* 2019;171:107–116.
- Giovanelli L et al. *J Endocrinol Invest.* 2021;44(8):1581–96.
- Aresta C et al. *Endocr Pract.* 2021;27(12):1216–24.
- Catargi B et al. *J Clin Endocrinol Metab.* 2003;88(12):5808–13.
- Costa DS et al. *J Diabetes Complications.* 2016;30(6):1032–8.
- León-Justel A et al. *J Clin Endocrinol Metab.* 2016;101(10):3747–54.
- Steffensen C et al. *Horm Metab Res.* 2019;51(1):62–8.
- Chiodini I et al. *Eur J Endocrinol.* 2005;153(6):837–44.
- Terzolo M et al. *J Clin Endocrinol Metab.* 2012;97(10):3467–75.
- Fassnacht M et al. *Management of adrenal incidentalomas: a European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.* 2023.
- Zeiger MA et al. *Endocr Pract.* 2009;15(5):450–3.

Acknowledgements

This study is funded by Corcept Therapeutics Incorporated. Medical writing assistance was provided by Huixuan Liang, PhD, and Tina K Schlafly, PhD, CMPP, of Corcept Therapeutics.

CATALYST Study Design

- A unique, 2-part phase 4 study to be conducted at approximately 30 sites in the United States (NCT05772169)



Part 1

- To assess the **prevalence of hypercortisolism** in persons with difficult-to-control T2D despite receiving multiple anti-hyperglycemic agents
 - **Screening:** 1-mg overnight DST with cortisol >1.8 µg/dL and dexamethasone ≥140 ng/dL
 - Further characterization with ACTH, DHEAS, cortisol, and adrenal CT
 - Those with ACTH-dependent disease will be referred for care outside of the study.
 - Those with surgically amenable disease will be informed of this treatment option.

Part 2

- To assess the tolerability, safety, and efficacy of treatment with the competitive glucocorticoid receptor antagonist Korlym (mifepristone) in persons with T2D and hypercortisolism identified in Part 1
 - **Study design:** Prospective, randomized, double-blind, placebo-controlled trial
 - **Stratification:** Presence/absence of adrenal adenoma(s) (based on non-contrast adrenal CT)
 - Study drug initiated at 1 tablet (300 mg) per day and titrated to 2 tablets (600 mg) per day at week 4. Dose titration is individualized.
 - Study drug may be titrated to 3 tablets (900 mg) per day.

Key Inclusion and Exclusion Criteria

	Key Inclusion	Key Exclusion
Part 1	<ul style="list-style-type: none"> • Adults (18-80 years old) with T2D • HbA1c ≥7.5% and ≤11.5%, AND taking <ul style="list-style-type: none"> ◦ ≥3 anti-hyperglycemic drugs OR ◦ insulin and other anti-hyperglycemic drug(s) OR ◦ ≥2 anti-hyperglycemic drugs AND <ul style="list-style-type: none"> – presence of ≥1 micro-vascular or macro-vascular complication AND/OR – concomitant hypertension requiring ≥2 anti-hypertension medications 	<ul style="list-style-type: none"> • Type 1 diabetes mellitus • Prior diagnosis of Cushing syndrome or past, current, or planned use of Cushing syndrome treatments • Night shift worker, alcohol excess, severe untreated sleep apnea • Severe medical, surgical, or psychiatric stress • On oral contraceptive pills and unable to hold for 3–4 weeks pre-DST • Exposure to systemic glucocorticoid medications (excluding inhalers or topical) within 3 months of screening
Part 2	<ul style="list-style-type: none"> • Completed Part 1 with DST >1.8 µg/dL and dexamethasone level ≥140 ng/dL • No increase or initiation of new anti-hyperglycemic medications within 4 weeks prior to first dose 	<ul style="list-style-type: none"> • Korlym use contraindicated • Refractory hypokalemia • Poorly controlled hypothyroidism or hyperthyroidism • Severe, poorly controlled hypertension (mean systolic BP >160 mm Hg or mean diastolic BP >100 mm Hg)